Affibody molecules |
Z domain of Protein A |
6 |
ABY-025 |
Phase II
(NCT01216033) |
|
Tumor imaging |
Affilins (Anticalins) |
Ubiquitin or Lipocalins |
10-20 |
PRS-080 |
Phase I/II (NCT02754167) |
|
Anemia |
Affimers (Adhirons) |
Cystatin |
12–14 |
Anti-PD-L1 Affimer |
|
(Basran & Stanley, 2018) |
Cancer
treatment |
Alphabodies |
Triple helix coiled coil |
10 |
CMPX-1023 |
|
(Desmet et al., 2014) |
Autoimmune
disease |
Avimers |
A domains of various membrane receptors |
9-18 |
C326 (AMG220) |
Phase I (NCT00353756) |
|
Crohn’s disease |
DARPins
|
Ankyrin repeat motif
|
14-21
|
Abicipar
|
Phase III (NCT02462486,
NCT02462928)
|
|
Age-related macular degeneration (AMD)
|
Domain antibodies
|
Engineered human single-domain Ig scaffold
|
11-15
|
CEP37247/PN0621/
ART621
|
Phase II NCT00928317
|
|
Treat autoimmune diseases
|
Fynomers |
Src homology 3 (SH3) domain of Fyn |
7 |
COVA322 |
Phase I/II
(NCT02243787) |
|
Plaque psoriasis |
Kunitz domain peptides
|
Kunitz domains of various protease inhibitors
|
7
|
Ecallantide (DX88)
Depelstat (DX890)
|
FDA approved in 2012
Phase II (NCT00455767)
|
|
Hereditary angioedema
Pulmonary fibrosis
|
Knottin |
Three anti-parallel β-strands connected |
4 |
Ziconotide
(Prialt) |
FDA approved in 2012 |
|
Neuropathic pain |
Monobodies (Adnectins) |
10th type III domain of fibronectin |
10 |
BMS-986089 |
Phase II (NCT02515669) |
|
Duchenne muscular
dystrophy |
β-Hairpin mimetics |
β-Hairpin motif |
1-2 |
POL6326 |
Phase I
(NCT01837095) |
|
Tumor suppressor |
Monobodies (Adnectins) |
10th type III domain of fibronectin |
10 |
BMS-986089 |
Phase II (NCT02515669) |
|
Duchenne muscular
dystrophy |